|Program||Target(s)||Indication(s)||Discovery||IND-enabling||Phase 1||Phase 2||Phase 3||Commercial rights|
|CRG-022 (CAR T)||CD22||R/R LBCL - post CD19 CAR T|
|CRG-022 (CAR T)||CD22||LBCL - CAR T naïve(1)|
|CRG-022 (CAR T)||CD22||Pediatric B-ALL|
|CRG-023 (tri-specific CAR T with CD2 co-stimulation)||CD19
(1) Based on data from the Phase 1 clinical trial conducted by Stanford and pending data from our ongoing Phase 2 trial in R/R LBCL – post CD19 CaAR T, we intend to discuss with the FDA initiation of a Phase 2 program in LBCL – CAR T naïve without completing earlier clinical trials in LBCL – CAR T-naïve patients.